Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient... Read More

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome... Read More

Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, but also significantly expands and activates both key types of γδ T cells (Vδ1+ and Vδ2+),... Read More

Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. NEW YORK, May... Read More

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation & Cellular Therapy (TCT) Meetings On May 1 st , 2025, we celebrated the 5 th anniversary of the first patient ever treated with a gamma-delta T cell therapy... Read More

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new clinical and preclinical data from its pipeline of gamma-delta T cell therapies at several upcoming scientific conferences. “The breadth of data we’re presenting at upcoming medical... Read More

First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release syndrome (CRS) INB-600 TCE platform significantly expands both Vδ1+ and Vδ2+ subsets to address the reduced cell counts that have limited earlier γδ TCE therapies in cancer patients INB-619 (CD19) and... Read More

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced today a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place... Read More

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB) , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360° (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA. William Ho, Chief Executive Officer and co-founder of... Read More

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free Expanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE) targeting CD19 for potential use in oncology and autoimmune diseases Continued operational execution with... Read More

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency INB-619, a next generation γδ TCE targeting CD19, eradicates B cells in preclinical models, maintaining depletion over time as γδ T cells expand in response to TCE stimulation γδ TCE targets and expands both Vδ1+ and Vδ2+ T cells, potentially leading to longer lasting immune... Read More

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB) , a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 45 th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. A live webcast and replay will be available under "Events and Presentations" in... Read More

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB) , a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the: H.C. Wainwright 3 rd Annual Cell Therapy Virtual Conference Date/Time Tuesday, February 25, 2025, at 11:00 a.m. ET. Webcast Link... Read More

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- February 14, 2025 – IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy (TCT) Meetings in Hawaii. The data, previously announced, reinforce INB-100’s potential to significantly... Read More

100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year progression-free survival (PFS) and overall survival (OS), exceeding real-world control groups Patients treated with INB-100 demonstrating prolonged and durable remissions supported by gamma-delta T cell persistence beyond... Read More

INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up of 19.7 months. Data highlights INB-100’s long-term impact, exhibiting durable in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration of INB-100, demonstrating the... Read More

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3, 2024 at 10:30 am ET. A high-definition video webcast of the presentation will be... Read More

50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median overall survival (OS) from standard-of-care Stupp regimen while none of the patients who received a single dose (n=3) achieved this outcome. Biopsy results confirmed the presence and persistence of gamma-delta T cells along with CD3+ and CD8+ T cells within the brain tumor microenvironment in two patients following... Read More

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial INB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel... Read More

Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta T cells for newly diagnosed glioblastoma (GBM) NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming plenary oral presentation at the 29... Read More

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA. Details for the ASH 2024 presentation are as follows: Title : INB-100: Pilot... Read More

Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing expansion cohorts in the Phase 1 trial of INB-100 for patients with Acute Myeloid Leukemia (AML) NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that it has... Read More

Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additional patients into the expansion cohort to further support the observed 100% progression-free survival in AML patients as of August 30, 2024. Suspending enrollment of Phase 2 clinical trial of INB-400 in newly diagnosed GBM; will continue to monitor patients for long-term remissions and... Read More

NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB) , a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the: H.C. Wainwright 26th Annual Global Investment Conference Format Fireside Chat Date/Time Monday, September 9, 2024, at 2:30 p.m. ET. A live webcast and replay will be... Read More

Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025. Early clinical data from investigator sponsored trials demonstrates prolonged relapse-free survival across both AML and glioblastoma (GBM) programs, compared to current standard-of-care, with both programs advancing to Phase 2... Read More

Presented positive Phase 1 data showing 100% 1-year complete remission (CR) in evaluable patients with hematologic malignancies including acute myelogenous leukemia (AML) for INB-100 at the European Hematology Association (EHA) 2024 Congress Continues to be an industry leader in the manufacturing and the clinical advancement of gamma-delta T cells for the treatment of solid and hematologic cancers Demonstrated robust and... Read More

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the H.C. Wainwright 2 nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 2:30 p.m. ET. A live webcast and replay will be... Read More

100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence... Read More

92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen) Majority of fully dosed patients exceeded the expected median PFS based on age and tumor status; one patient from Cohort 2 remains alive and progression free at almost three years Radiologic evaluation indicative of “treatment effect”... Read More

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28 th to June 1 st in Vancouver, Canada. “ISCT is a scientific gathering renowned for fostering groundbreaking ideas and innovation in cellular... Read More

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming presentation of updated results from its fully enrolled Phase 1 study of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 31st - June 4th in Chicago, Illinois. INB-200 is evaluating... Read More

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain. “We’re excited to share the latest updated interim results from our Phase 1 trial evaluating our gamma-delta T cell therapy INB-100 after... Read More

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting. In an oral... Read More

Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue Demonstrated potential of nsCAR platform to treat previously “undruggable” solid and liquid tumor targets Announced peer-reviewed publication in ‘Frontiers in Immunology’ on IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI) approach to... Read More

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, announced today that the first patient in its Phase 2 clinical trial evaluating INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM) has been successfully dosed at the Cleveland Clinic in Ohio. INB-400 is the Company’s first autologous... Read More

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. Details of the oral presentation are as follows: Title: Healthy Donor vs Patient... Read More

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 th at 12:30pm ET. The formal presentation will feature a fireside style Q&A session with... Read More

Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue Gamma-delta nsCAR platform emerging as an advanced technology for targeting hematologic and solid tumor cancers NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today... Read More

Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated Remained in Remission, including six Patients Alive and Progression Free Past 12 Months Presented Positive Results from a Phase 1 Study in Newly Diagnosed Glioblastoma (GBM) Demonstrating All Patients Treated with INB-200 Exceeded Progression-Free Survival... Read More

New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented. The platform has demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigens, which could be used for previously “undruggable” solid and liquid tumor targets. NEW YORK, March 05, 2024 (GLOBE... Read More

NEW YORK / Feb 26, 2024 / Business Wire / IN8bio, Inc . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the following investor conferences in March: TD Cowen 44 th Annual Health Care Conference Company presentation Monday, March 4, 2024, at 9:50 am ET 2nd Annual H.C. Wainwright Cell... Read More

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer. Cellular therapies, particularly chimeric antigen receptor T cell therapies... Read More

Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored trial of INB-100 at the 65 th American Society of Hematology (ASH) Annual Meeting & Exposition Presented new data at Society for Neuro-Oncology (SNO) 28 th Annual Meeting highlighting the potential of INB-200 and INB-400 to treat patients with newly diagnosed... Read More

Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple prior lines of therapy, including CAR-T. All trial participants remain alive and relapse free as of last assessment, and six patients have been relapse free for over one year. New data shows long-term in-vivo expansion and persistence of allogeneic... Read More

Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations Proceeds to help accelerate advancement of the Company’s gamma-delta T cell therapies NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta... Read More

Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancers Board-Certified physician-scientist with deep experience at leading organizations such as Bristol Myers Squibb, Iovance Biotherapeutics, the National Cancer Institute (NCI), Goldman Sachs and most recently CARGO Therapeutics NEW YORK, Dec. 07, 2023 (GLOBE... Read More

Event will follow the presentation of INB-100 data in patients with hematologic malignancies at the American Society of Hematology (ASH) 65 th Annual Meeting & Exposition on the evening of December 11, 2023 IN8bio’s management team will be joined by clinical thought leader Michael Bishop, MD, Director of the David and Etta Jonas Center for Cellular Therapy at The University of Chicago The live webcast can be accessed here... Read More

All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and tumor status; two patients from Cohort 2 remain alive beyond two years Additional enrolled patients await dosing with completion of enrollment in Cohort 3 expected in 2023 and long-term follow up to be presented at medical... Read More

Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200 Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs) poster NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that the Company will present two posters... Read More

Completed dose escalation in Phase 1 Trial of INB-100 with updated clinical data to be presented at the American Society of Hematology (ASH) Annual Meeting on December 11, 2023 (Abstract Number: 4853 ). Held Research & Development Day, featuring Leo Luznik, M.D. from Johns Hopkins University and Michael Bishop, M.D. from The University of Chicago, highlighting IN8bio’s differentiated clinical and scientific programs and... Read More

Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune response. A treated patient, with paired tissue biopsies, demonstrated infiltration of gamma-delta T cells 148 days following a single administration in Cohort 1. Updated patient, survival and enrollment data from the ongoing INB-200... Read More

This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential to produce billions of iVδ1 T cells. IN8bio's iVd1+ subtype cells have an expression profile linked to a low risk of cytokine release syndrome (CRS) and have shown strong cancer-killing abilities against various solid and liquid... Read More

New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; updated data on durability of responses and long-term complete responses (CRs) to be presented. INB-100 continues to demonstrate a favorable safety profile with no dose-limiting toxicities (DLTs) and evidence of robust gamma-delta T cell expansion using recommended Phase 2 dose... Read More

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in 1x1 meetings at the Truist Securities BioPharma Symposium being held Wednesday, November 8 and Thursday, November 9, 2023, in New York, NY. The company expects multiple preclinical and... Read More

Enrollment is now open in the company-sponsored Phase 2 clinical trial of INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM). Enrollment completed in the dose escalation phase of the investigator-sponsored trial of INB-100 in leukemia patients with a clinical update expected at the American Society of Hematology (ASH) Annual Meeting. R&D Day held today, October 12, 2023 (9:00am-12:00pm EDT). Register... Read More

NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced two poster presentations reporting positive data at the Society for Immunotherapy of Cancer’s (SITC) 38 th Annual Meeting, taking place November 1-5, 2023, in San Diego, CA. The presentations will showcase biological correlative data... Read More

Management presentations will highlight IN8bio’s clinical and scientific programs, including upcoming data releases at several upcoming fall medical meetings Featured presentations by clinical thought leaders including Leo Luznik, M.D., Professor of Oncology at Johns Hopkins Medicine and Michael Bishop, M.D., Director of the David and Etta Jonas Center for Cellular Therapy at The University of Chicago NEW YORK, Sept. 26,... Read More

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023, at 8:35 a.m. ET. The Cantor Fitzgerald presentation will be available... Read More

Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell (CAR-T) and checkpoint inhibitors (CPIs). Broadens IN8bio’s foundational intellectual property (IP) for its proprietary DeltEx DRI platform which covers the use of any genetic modification that conveys chemotherapy resistance in gamma-delta T cells, as well as natural killer (NK) cells.... Read More

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in a fireside chat at the H.C. Wainwright 25 th Annual Global Investment Conference on Wednesday, September 13, 2023 at 2:00 p.m. ET. The H.C. Wainwright presentation will be available... Read More

NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in a fireside chat at the H.C. Wainwright Immune Cell Engager Virtual Conference on Thursday, August 17, 2023 at 2:00 pm ET. The H.C. Wainwright presentation will be available live and as... Read More

Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting showing 100% of treated patients (n=8) have exceeded historical median progression-free survival INB-400 on track to initiate enrollment in glioblastoma multiforme (GBM) in the second half of 2023. The Phase 2 trial ( NCT05664243 ) will initially enroll newly diagnosed GBM patients in the... Read More

State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell therapies The new site supports IN8bio’s commitment to develop a strong biotechnology presence in the Birmingham region NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing... Read More

100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two patients that received three doses remaining progression-free at 23.5 and 19.4 months, respectively. INB-200 continues to exhibit a manageable safety profile with minimal toxicities and repeat dosing demonstrated no change in the toxicity profile. Company is on track to complete INB-200 Phase 1 study enrollment in 2023... Read More

Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid tumors beyond the brain The DeltEx platform is the basis for IN8bio’s clinical stage gamma-delta T cell therapeutic candidates and demonstrated the ability to target and kill multiple ovarian cancer cell lines NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a... Read More

Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated leukemia patients; Dose Level 2 selected as the recommended Phase 2 dose (RP2D) for the ongoing expansion with clinical updates expected in late 2023 Progress across preclinical programs, including data demonstrating that gamma-delta T cells have the ability to target other solid... Read More

Preclinical data demonstrates that gamma-delta T cells have the ability to target other solid tumors such as ovarian cancer, supporting the development of these technologies outside of brain tumors The data suggest that INB-400, a clinical stage genetically engineered gamma-delta T cell therapeutic candidate, has the potential to be developed as a novel therapy for ovarian cancer, offering hope for patients with this... Read More

Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly’s oncology portfolio He is a highly respected industry leader in oncology with a track record of success in advancing multiple novel anti-cancer compounds into and through the clinic and has been instrumental in garnering the approval of several oncology... Read More

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from June 2-6, 2023. The oral presentation will highlight new Phase 1 study results evaluating the safety,... Read More

First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation offers potential 7-year market exclusivity for both autologous (INB-400) and allogeneic (INB-410) candidates INB-400 is an autologous, genetically engineered gamma-delta T cell therapy that was recently cleared by the FDA for a Phase 2 trial targeting newly diagnosed glioblastoma multiforme (GBM) NEW YORK,... Read More

INB-100 treatment has achieved durable 100% complete remission (CR) in treated patients, including high-risk acute myeloid leukemia (AML) patients and a patient with acute lymphoblastic leukemia (ALL) who had failed 4 prior lines of therapy, including CAR-T, with all evaluable patients remaining alive at last assessment and one patient out beyond 3 years. The latest data shows that allogeneic gamma-delta T cell expansion and... Read More

INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigen. CAR platform leverages the ability of gamma-delta T cells to selectively target tumor cells supporting the potential of this approach in previously “undruggable” solid-and liquid-tumor targets. Company announces new INB-330 program... Read More

Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated with INB-100 will be presented; no dose-limiting toxicities have been observed New correlative data on immune reconstitution and gamma-delta T cell proliferation for Cohorts 1 and 2 will be presented NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company... Read More

All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months and up to 2.7 years in an ongoing Phase 1 trial of INB-100 as of December 9, 2022; Updated clinical data to be reported at the EBMT Annual Meeting in April 2023 INB-200 continued to show durable and favorable responses, with ongoing patients extending beyond 1.5 years and 1.2 years progression free through year-end... Read More

INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving healthy tissue. Data supports the potential for this next-generation CAR-T technology in previously “undruggable” solid- and liquid-tumor targets. NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and... Read More

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a company overview at the Cowen 43 rd Annual Healthcare Conference on Tuesday, March 7, 2023 at 12:50 pm ET. The Cowen presentation will be available live and as a replay on IN8bio’s... Read More

Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. Greater than 15x difference in killing between tumor cells and healthy B cells with the non-signaling gamma-delta CAR-T platform (nsCAR) utilizing the validated target of CD19 as proof-of-concept. Leveraging the unique properties of gamma-delta T cells supports the potential to broaden the utilization of CAR technology for... Read More

NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 1:30 pm ET. The H.C. Wainwright presentation will be available live and as a... Read More

NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a company overview at the B. Riley Securities’ 3 rd Annual Oncology Conference on Wednesday, January 18, 2023 at 12:00pm ET. Interested parties can register for the webcast using the... Read More

All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial data from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastoma multiforme (GBM). Company-sponsored Phase 2 multi-center clinical trial of autologous INB-400 gamma-delta T cells in newly diagnosed GBM patients to... Read More

Company to be in San Francisco January 9-11, 2023, during the 41st Annual J.P. Morgan Healthcare Conference NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present at Biotech Showcase 2023 on Monday, January 9, 2023, and will also... Read More

Results from the first cohort of patients with hematological malignancies show patients remained progression free; ongoing durations of response extend beyond 2.5 years (31.9 months) INB-100 continues to demonstrate a manageable safety profile with no dose-limiting toxicities (DLTs) observed to date Enrollment for Cohort 2 has been initiated with additional clinical updates expected in 2Q 2023 Company to host conference call... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, CEO and co-founder, will be presenting at two investor conferences in November. BioFuture 2022 , November 8, 2022 Next-Generation Cancer Therapeutics: Multiple Approaches Showing Promise panel at 9:30 a.m. ET Corporate... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced that William Ho, IN8bio’s Chief Executive Officer, will be a speaker on the “Cell Therapy in Solid Tumors” panel at the Cantor Oncology & HemOnc Conference. The panel will take place at 1:45 p.m. ET on September 28, 2022. About IN8bio... Read More

Agreement provides exclusive access to state-of-the-art GMP manufacturing suites to support Phase 2 clinical studies Potential to expand the agreement to support commercial-scale manufacturing IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, IN8bio’s Chief Executive Officer will be participating in a fireside chat at 10:30 a.m. ET tomorrow, Wednesday, September 14, at the H.C. Wainwright & Co. 24 th Annual Global Investment Conference. The fireside chat will be... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has appointed Michael R. Bishop, M.D., F.A.C.P., F.A.S.C.O., to its Scientific Advisory Board (SAB). Dr. Bishop is Director, Hematopoietic Cellular Therapy Program, and Director of the David and Etta Jonas Center for Cellular Therapy,... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced the presentations it will be making at investor and scientific conferences in September 2022. Citi’s Annual BioPharma Conference (Boston), September 7 – 8 William Ho, CEO, will participate on the Cell Therapy Panel September 7, 3:30 p.m.... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that the underwriter of its previously announced underwritten public offering of common stock which closed on August 16, 2022 has partially exercised its option to purchase an additional 268,949 shares at the public offering... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the closing of its previously announced underwritten public offering of 5,394,737 shares of its common stock at a public offering price of $1.90 per share. The aggregate gross proceeds from the offering, before deducting... Read More

Unveiled a new preclinical program focused on developing iPSC derived gamma-delta T cells and presented early findings at the ASGCT Annual Meeting. Presented data from Phase 1 clinical trial of INB-200 in patients with newly diagnosed GBM showing five of six fully dosed patients exceeded both median and expected progression free survival (PFS), with a sixth patient early in follow up; two patients have exceeded overall... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the pricing of an underwritten public offering of 5,394,737 shares of its common stock at a public offering price of $1.90 per share. IN8bio also granted the underwriter a 30-day option to purchase up to an additional 657,894... Read More

All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and progression-free after at least one year. Patients remain in morphological complete remission (CR) with two patients over two years and a third over one year post-transplant, respectively. Safety profile continues to be manageable with no dose-limiting toxicities, no... Read More

European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cells Patent portfolio broadly covers chemotherapy resistant engineering of innate immune cells for cellular therapy, providing the basis for IN8bio’s Drug Resistant Immunotherapy platform IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company... Read More

IN8bio, Inc. (Nasdaq: INAB) , a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced an appointment to its executive team to lead the Company’s business development efforts. Kenneth R. LaMontagne, Ph.D., joins the company as Senior Vice President, Business Development, to advance the company’s partnership... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced July conference presentations: Oppenheimer Summit for Emerging Biotechnology (Montauk), July 20 Patrick McCall, CFO, and Dr. Trishna Goswami, CMO, open scheduling for 1x1 partnering 3 rd Annual Gamma-Delta T Cell Therapies... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, announced that William Ho, CEO will be presenting today at 1:30pm EDT at the Jefferies Global Healthcare Conference. A live audio webcast of the presentation will be available and via the Company’s Investor Relations page following the... Read More

100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two patients, to date, having exceeded their expected overall survival (OS). An unmethylated GBM patient remains stable at one-year post enrollment. Patient received three-repeated doses and is without disease progression, has doubled expected PFS and remains off steroids. All patients dosed demonstrating a manageable safety and... Read More

IN8bio recently unveiled expansion of its DeltEx gamma-delta T cell platform capabilities to include induced pluripotent stem cells (iPSCs). Yesterday, at the American Society for Gene & Cell Therapy (ASGCT) 25 th Annual Meeting, IN8bio announced data on its iPSC platform showing that our iPSC-derived gamma-delta T cells demonstrated robust cytotoxicity and can be genetically modified with an internally developed chimeric... Read More

Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate encouraging data. INB-100 patient update at European Group for Blood and Marrow Transplantation (EBMT) 48th Annual Meeting demonstrated that all three treated patients remain in morphologic complete response (CR) with two patients approaching relapse free survival of 21 to 23... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced the Company’s new induced pluripotent stem cell (iPSC) based gamma-delta T cell platform. We have demonstrated that we are one of the few companies than can differentiate iPSC-derived immune cells and the first to produce both iPSC-derived Vdelta1 (Vd1+) and Vdelta2... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced May conference presentations: ISCT International Society for Cell & Gene Therapy (San Francisco), May 4 – 7, 2022 Guoling Chen, MD/MBBS, MS, and Caitlyn Lucas, MS, will present “Logistic Management for Expanded Activated... Read More

Urvashi Patel, Ph.D., as Vice President, Regulatory Affairs Stacey Bilinski, as Vice President, Clinical Operations IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the additions to its clinical and regulatory team as the Company seeks to expand its clinical pipeline with... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced April conference presentations: American Association for Cancer Research (AACR) Annual Meeting 2022 (New Orleans), April 8 – 13, 2022 Lawrence Lamb, Ph.D., CSO, will present “Maintenance-Phase Temozolomide as a... Read More

All three patients with high-risk or relapsed acute-myeloid leukemia (AML) dosed to-date with INB-100 demonstrated durable remissions at 23.3, 21.0, and 9.3 months post-BMT, respectively. Immune systems robustly reconstituted in patients at six months post-treatment with INB-100, including T cells, B cells, and gamma-delta T cells. Safety profile continues to be manageable with no dose-limiting toxicities, no... Read More

All patients treated with INB-200, in clinical development for the treatment of glioblastoma multiforme (GBM), have shown a well-tolerated safety profile and longer than anticipated progression free survival (PFS) to date. All patients treated with INB-100, in clinical development for the treatment of leukemia undergoing hematopoietic stem cell transplantation (HSCT), have remained in remission, two for more than 1.5 years.... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company, today announced March conference presentations: European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress 2022 (virtual), March 7 – 8, 2022 Kate Rochlin, Ph.D., COO ePoster: 23P - Engineered chemotherapy resistant γδ T-cells with combinatorial chemotherapies can enhance tumor cell immunogenicity and... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company today announced that Company executives will be presenting at the following events: BIO CEO & Investor Conference, February 14 - 17, 2022 Will Ho, Chief Executive Officer, will present a company overview Available On-Demand February 14 - 17, 2022 Visit https://www.bio.org/events/bio-ceo-investor-conference/sessions#2022-02-16... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive Officer and co-founder of IN8bio, will present at four upcoming virtual investor conferences in January. Event: H.C. Wainwright & Co. BioConnect Conference Presentation: On-demand virtual... Read More

INB-200 is the first-ever genetically modified gamma-delta T cell therapy in clinical trials and is currently in a repeated-dose escalation cohort Cohort 1 dosing is complete with three patients who received a single dose of INB-200 with no dose limiting toxicities (DLTs), cytokine release syndrome (CRS), or neurotoxicity, and a manageable safety profile Cohort 2 is enrolling with one patient having received all three doses... Read More

The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of allogeneic gamma-delta T cells to patients 3 patients have been treated to date, all of whom remain in remission with the first two patients at ~20 months and ~18 months post treatment, respectively, and the most recent at ~6 months Of the 3 patients that were dosed with INB-100, all have achieved and... Read More

IN8bio, Inc. (Nasdaq: INAB) , a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its proprietary DeltEx platform, today announced the promotion of Kate Rochlin, Ph.D. to Chief Operating Officer (COO). Dr. Rochlin previously served as Vice President, Operations and Innovation. Dr. Rochlin will be responsible for multiple functional areas,... Read More

IN8bio, Inc. (Nasdaq: INAB) , a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the appointment of Trishna Goswami, M.D. as Chief Medical Officer. “Trishna’s experience and skills as a leader in immuno-oncology drug development aligns perfectly with our goals to advance multiple gamma-delta T cell... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its proprietary DeltEx platform, today announced a poster presentation of preclinical data demonstrating the potential of its cellular therapies in combination with Poly (ADP-ribose) polymerase (PARPi) and checkpoint inhibitors, which may enhance the recognition... Read More

Closed initial public offering raising net proceeds after expenses of $32.3 million. Added two new independent Directors and increased diversity across our Board of Directors. Completed patient dosing of the first cohort of a Phase 1 clinical trial of INB-100 in leukemia patients undergoing hemopoietic stem cell transplant. Announced peer-reviewed publication of preclinical data for INB-200 in Scientific Reports, a Nature... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced presentations at three scientific conferences in November. Event: Protein & Antibody Engineering Summit (PEGS) Europe Presenter: Lawrence Lamb, Ph.D., Executive Vice President, Chief Scientific Officer and co-founder of... Read More

Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of high-grade glioma MGMT-modified gamma-delta T cells are engineered to survive chemotherapy and form the basis of IN8bio’s Drug Resistant Immunotherapy (DRI) technology These results, published online in the Nature portfolio journal Scientific Reports (DOI:... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive Officer and co-founder of IN8bio, will present a company overview as well as participate on an Oncology panel at BioFuture 2021. Kate Rochlin, Vice President, Operations and Innovation of... Read More

First cohort dosing completed in Phase 1 clinical trials of INB-200 and INB-100 Data presentations made at ASCO and AACR $40M initial public offering (IPO) in August 2021 to fund continuing operations IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced financial results and... Read More

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, President, Chief Executive Officer and co-founder of IN8bio, will present at the NewYorkBIO Virtual Breakfast Series and the virtual H.C. Wainwright 23 rd Annual Global Investment Conference. Event:... Read More

The first cohort has completed dosing with IN8bio’s donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs) observed to date The first two patients continue to be in complete remission more than one year following INB-100 dosing IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and... Read More

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, announces the appointments of Emily Fairbairn and Luba Greenwood as new members of its Board of Directors. “Emily and Luba have vast experience as entrepreneurs, executives, board members and... Read More